These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31944407)

  • 1. RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome.
    Hamlett ED; Hjorth E; Ledreux A; Gilmore A; Schultzberg M; Granholm AC
    Glia; 2020 Jul; 68(7):1347-1360. PubMed ID: 31944407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.
    Lockrow J; Boger H; Gerhardt G; Aston-Jones G; Bachman D; Granholm AC
    J Alzheimers Dis; 2011; 23(3):471-89. PubMed ID: 21098982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease.
    Kantarci A; Aytan N; Palaska I; Stephens D; Crabtree L; Benincasa C; Jenkins BG; Carreras I; Dedeoglu A
    Exp Neurol; 2018 Feb; 300():111-120. PubMed ID: 29126887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
    Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
    Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer receptors enhance memory in a mouse model of Down syndrome.
    Fortress AM; Hamlett ED; Vazey EM; Aston-Jones G; Cass WA; Boger HA; Granholm AC
    J Neurosci; 2015 Jan; 35(4):1343-53. PubMed ID: 25632113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
    Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
    Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome.
    Hamlett ED; Ledreux A; Gilmore A; Vazey EM; Aston-Jones G; Boger HA; Paredes D; Granholm AE
    Neurobiol Dis; 2020 Feb; 134():104616. PubMed ID: 31678403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice.
    Rueda N; Vidal V; García-Cerro S; Narcís JO; Llorens-Martín M; Corrales A; Lantigua S; Iglesias M; Merino J; Merino R; Martínez-Cué C
    Brain Behav Immun; 2018 Oct; 73():235-251. PubMed ID: 29758264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice.
    Ahmed MM; Wang AC; Elos M; Chial HJ; Sillau S; Solano DA; Coughlan C; Aghili L; Anton P; Markham N; Adame V; Gardiner KJ; Boyd TD; Potter H
    Neurobiol Dis; 2022 Jun; 168():105694. PubMed ID: 35307513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
    Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
    Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
    Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
    J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.
    Kazim SF; Blanchard J; Bianchi R; Iqbal K
    Sci Rep; 2017 Apr; 7():45561. PubMed ID: 28368015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
    Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
    Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
    Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen.
    Hunter CL; Bimonte-Nelson HA; Nelson M; Eckman CB; Granholm AC
    Neurobiol Aging; 2004 Aug; 25(7):873-84. PubMed ID: 15212841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease.
    Strupp BJ; Powers BE; Velazquez R; Ash JA; Kelley CM; Alldred MJ; Strawderman M; Caudill MA; Mufson EJ; Ginsberg SD
    Curr Alzheimer Res; 2016; 13(1):97-106. PubMed ID: 26391046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome.
    Lysenko LV; Kim J; Henry C; Tyrtyshnaia A; Kohnz RA; Madamba F; Simon GM; Kleschevnikova NE; Nomura DK; Ezekowitz RA; Kleschevnikov AM
    PLoS One; 2014; 9(12):e114521. PubMed ID: 25474204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience-dependent reduction of soluble β-amyloid oligomers and rescue of cognitive abilities in middle-age Ts65Dn mice, a model of Down syndrome.
    Sansevero G; Begenisic T; Mainardi M; Sale A
    Exp Neurol; 2016 Sep; 283(Pt A):49-56. PubMed ID: 27288239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.